Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a single-center, uncontrolled pilot study with no comparator group and an estimated enrollment of only 13 participants, designed to assess feasibility and biological effect on a surrogate endpoint (endotoxin level) rather than clinical outcomes.
This is a recruiting Phase 4 interventional trial with no results posted; the registry record describes only the planned design and safety endpoints, not outcomes.
A post-hoc analysis from a controlled trial showing no safety signal for dapagliflozin in critically ill AKI patients, with near-neutral effects and physiological stability, but underpowered to detect clinically meaningful benefit or harm.
Observational study with target trial emulation found no significant association between amino acid therapy and AKI, though hypothesis-generating subgroup signal in older patients.